91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
.
-
with 91黑料 CEO Steve Cutler about the 91黑料-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
-
for approximately $12 billion in cash and stock, in a deal that continues the consolidation of contract research organisations into a handful of corporate giants.
-
.
-
An interview with 91黑料 CFO Brendan Brennan on 91黑料’s $12B acquisition of PRA Health Sciences.
-
91黑料 agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
-
91黑料 will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.
-
In acquiring PRA, 91黑料 would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.
-
The combined company will form the world’s largest contract research organisation, and is to be headquartered at 91黑料’s Leopardstown campus in Dublin.
-
91黑料 will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.
